Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasm Metastasis 5Prostatic Neoplasms 4Sarcoma 3Neoplasms 3Pancreatic Neoplasms 2Neuroblastoma 2Hodgkin Disease 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Soft Tissue Neoplasms 1Recurrent Uterine Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphangioleiomyomatosis 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Imatinib Mesylate 23Cyclophosphamide 18fludarabine 17fludarabine phosphate 13Busulfan 12Whole-Body Irradiation 11nilotinib 10Dasatinib 9thymoglobulin 8ponatinib 8Mycophenolic Acid 8Cytarabine 7Antilymphocyte Serum 7peginterferon alfa-2b 6Tacrolimus 6Cyclosporine 6Clofarabine 6Thiotepa 5Stem Cell Transplantation 4Sirolimus 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Alemtuzumab 4sargramostim 3Interferon-alpha 3Homoharringtonine 3Cord Blood Stem Cell Transplantation 3Bortezomib 3zileuton 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × temsirolimus × Clear all
NCT00101088 2013-01-14

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
21 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡